D. Bell et al.: Integrated genomic analyses of ovarian carcinoma. In: Nature. 30. Juni 2011, Nr. 474, S. 609–615, doi:10.1038/nature10166
Philippe Morice, Sebastien Gouy, Alexandra Leary: Mucinous Ovarian Carcinoma. In: New England Journal of Medicine. Band380, Nr.13, 28. März 2019, ISSN0028-4793, S.1256–1266, doi:10.1056/NEJMra1813254.
Lauren C Peres, Kara L Cushing-Haugen, Martin Köbel, Holly R Harris, Andrew Berchuck: Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage. In: JNCI: Journal of the National Cancer Institute. Band111, Nr.1, 1. Januar 2019, ISSN0027-8874, S.60–68, doi:10.1093/jnci/djy071, PMID 29718305, PMC 6335112 (freier Volltext) – (oup.com [abgerufen am 7. April 2019]).
V. A. Heinzelmann-Schwarz, M. Gardiner-Garden, S. M. Henshall, J. P. Scurry, R. A. Scolyer: A distinct molecular profile associated with mucinous epithelial ovarian cancer. In: British Journal of Cancer. Band94, Nr.6, 27. März 2006, ISSN0007-0920, S.904–913, doi:10.1038/sj.bjc.6603003, PMID 16508639, PMC 2361366 (freier Volltext).
J Alexandre, I Ray-Coquard, F Selle, A Floquet, P Cottu: Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience. In: Annals of Oncology: Official Journal of the European Society for Medical Oncology. Band21, Nr.12, Dezember 2010, ISSN1569-8041, S.2377–2381, doi:10.1093/annonc/mdq257, PMID 20494964.
Kuang-Leei Chang, Ming-Yung Lee, Wan-Ru Chao, Chih-Ping Han: The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma. In: Human Genomics. Band10, 28. Dezember 2016, ISSN1473-9542, doi:10.1186/s40246-016-0096-9, PMID 28031051, PMC 5192568 (freier Volltext).
R. A. Burger et al.: Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. In: N Engl J Med., 2011; 365, S. 2473–2483; PMID 22204724. doi:10.1056/NEJMoa1104390
Lauren C Peres, Kara L Cushing-Haugen, Martin Köbel, Holly R Harris, Andrew Berchuck: Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage. In: JNCI: Journal of the National Cancer Institute. Band111, Nr.1, 1. Januar 2019, ISSN0027-8874, S.60–68, doi:10.1093/jnci/djy071, PMID 29718305, PMC 6335112 (freier Volltext) – (oup.com [abgerufen am 7. April 2019]).
V. A. Heinzelmann-Schwarz, M. Gardiner-Garden, S. M. Henshall, J. P. Scurry, R. A. Scolyer: A distinct molecular profile associated with mucinous epithelial ovarian cancer. In: British Journal of Cancer. Band94, Nr.6, 27. März 2006, ISSN0007-0920, S.904–913, doi:10.1038/sj.bjc.6603003, PMID 16508639, PMC 2361366 (freier Volltext).
J Alexandre, I Ray-Coquard, F Selle, A Floquet, P Cottu: Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience. In: Annals of Oncology: Official Journal of the European Society for Medical Oncology. Band21, Nr.12, Dezember 2010, ISSN1569-8041, S.2377–2381, doi:10.1093/annonc/mdq257, PMID 20494964.
Kuang-Leei Chang, Ming-Yung Lee, Wan-Ru Chao, Chih-Ping Han: The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma. In: Human Genomics. Band10, 28. Dezember 2016, ISSN1473-9542, doi:10.1186/s40246-016-0096-9, PMID 28031051, PMC 5192568 (freier Volltext).
R. A. Burger et al.: Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. In: N Engl J Med., 2011; 365, S. 2473–2483; PMID 22204724. doi:10.1056/NEJMoa1104390
oup.com
academic.oup.com
Lauren C Peres, Kara L Cushing-Haugen, Martin Köbel, Holly R Harris, Andrew Berchuck: Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage. In: JNCI: Journal of the National Cancer Institute. Band111, Nr.1, 1. Januar 2019, ISSN0027-8874, S.60–68, doi:10.1093/jnci/djy071, PMID 29718305, PMC 6335112 (freier Volltext) – (oup.com [abgerufen am 7. April 2019]).
Philippe Morice, Sebastien Gouy, Alexandra Leary: Mucinous Ovarian Carcinoma. In: New England Journal of Medicine. Band380, Nr.13, 28. März 2019, ISSN0028-4793, S.1256–1266, doi:10.1056/NEJMra1813254.
Lauren C Peres, Kara L Cushing-Haugen, Martin Köbel, Holly R Harris, Andrew Berchuck: Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage. In: JNCI: Journal of the National Cancer Institute. Band111, Nr.1, 1. Januar 2019, ISSN0027-8874, S.60–68, doi:10.1093/jnci/djy071, PMID 29718305, PMC 6335112 (freier Volltext) – (oup.com [abgerufen am 7. April 2019]).
V. A. Heinzelmann-Schwarz, M. Gardiner-Garden, S. M. Henshall, J. P. Scurry, R. A. Scolyer: A distinct molecular profile associated with mucinous epithelial ovarian cancer. In: British Journal of Cancer. Band94, Nr.6, 27. März 2006, ISSN0007-0920, S.904–913, doi:10.1038/sj.bjc.6603003, PMID 16508639, PMC 2361366 (freier Volltext).
J Alexandre, I Ray-Coquard, F Selle, A Floquet, P Cottu: Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience. In: Annals of Oncology: Official Journal of the European Society for Medical Oncology. Band21, Nr.12, Dezember 2010, ISSN1569-8041, S.2377–2381, doi:10.1093/annonc/mdq257, PMID 20494964.
Kuang-Leei Chang, Ming-Yung Lee, Wan-Ru Chao, Chih-Ping Han: The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma. In: Human Genomics. Band10, 28. Dezember 2016, ISSN1473-9542, doi:10.1186/s40246-016-0096-9, PMID 28031051, PMC 5192568 (freier Volltext).